- Medline (MDLN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
May 7, 2026 · zacks.com
Although the revenue and EPS for Medline (MDLN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- Medline Inc. (MDLN) Q1 2026 Earnings Call Transcript
May 6, 2026 · seekingalpha.com
Medline Inc. (MDLN) Q1 2026 Earnings Call Transcript
- Medline Reports First Quarter 2026 Results
May 6, 2026 · globenewswire.com
Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance range to 8.5% to 9.5% NORTHFIELD, Ill., May 06, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care3, today reported its operating results for the three months ended March 28, 2026.
- MEDLINE REPORTS FIRST QUARTER 2026 RESULTS
May 6, 2026
NET SALES OF $7.4 BILLION, AN INCREASE OF 10.7% NET INCOME OF $239 MILLION, A DECREASE OF 25.8% ADJUSTED EBITDA 1 OF $776 MILLION, A DECREASE OF 10.6% RAISING FULL YEAR 2026 ORGANIC SALES 2 GUIDANCE RANGE TO 8.5% TO 9.5% NORTHFIELD, ILL., MAY 06, 2026 (GLOBE NEWSWIRE) -- MEDLINE INC. (“MEDLINE” OR THE “COMPANY”) (NASDAQ: MDLN), THE LARGEST PROVIDER OF MEDICAL-SURGICAL (“MED-SURG”) PRODUCTS AND SUPPLY CHAIN SOLUTIONS SERVING ALL POINTS OF CARE3, TODAY REPORTED ITS OPERATING RESULTS FOR THE THREE MONTHS ENDED MARCH 28, 2026.
- Parnassus Growth Equity Fund Q1 2026 Portfolio Activity
Apr 17, 2026 · seekingalpha.com
We are actively monitoring Meta Platforms' social and data privacy risks and believe the company has made progress on strengthening its policies and enforcement. We believe the market is underestimating the durability of Edwards' transcatheter aortic valve replacement franchise and the opportunity for its transcatheter mitral and tricuspid therapies. We exited our position in Workday to bring the portfolio's software exposure closer to market weight.
- Medline announces first-in-healthcare AI robotics partnership with Symbotic
Apr 16, 2026 · prnewswire.com
Continued investment in next-gen supply chain technology powers Medline's distribution capabilities NORTHFIELD, Ill., April 16, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN) announced a strategic agreement to implement next-generation warehouse automation from Symbotic, a leader in AI-enabled robotics technology, as part of the company's ongoing efforts to strengthen the resiliency, efficiency and scalability of the healthcare supply chain.
- MEDLINE ANNOUNCES FIRST-IN-HEALTHCARE AI ROBOTICS PARTNERSHIP WITH SYMBOTIC
Apr 16, 2026
CONTINUED INVESTMENT IN NEXT-GEN SUPPLY CHAIN TECHNOLOGY POWERS MEDLINE'S DISTRIBUTION CAPABILITIES NORTHFIELD, ILL., APRIL 16, 2026 /PRNEWSWIRE/ -- MEDLINE (NASDAQ: MDLN) ANNOUNCED A STRATEGIC AGREEMENT TO IMPLEMENT NEXT-GENERATION WAREHOUSE AUTOMATION FROM SYMBOTIC, A LEADER IN AI-ENABLED ROBOTICS TECHNOLOGY, AS PART OF THE COMPANY'S ONGOING EFFORTS TO STRENGTHEN THE RESILIENCY, EFFICIENCY AND SCALABILITY OF THE HEALTHCARE SUPPLY CHAIN.
- MDLN Gets FDA Warning for Quality Lapses in Angiographic Syringes
Apr 14, 2026 · zacks.com
MDLN faces FDA warning over cGMP lapses in angiographic syringes, citing weak quality controls, CAPA gaps and design flaws despite escalating share price.
- Baillie Gifford & Co. Takes Position in Medline $MDLN
Apr 13, 2026 · defenseworld.net
Baillie Gifford and Co. bought a new position in shares of Medline (NASDAQ: MDLN) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 10,410,371 shares of the company's stock, valued at approximately $437,236,000. Baillie Gifford and Co. owned 0.79% of Medline as of
- Medline (NASDAQ:MDLN) & MiniMed Group (NASDAQ:MMED) Head to Head Survey
Apr 13, 2026 · defenseworld.net
Medline (NASDAQ: MDLN - Get Free Report) and MiniMed Group (NASDAQ: MMED - Get Free Report) are both manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk. Profitability This table compares Medline and MiniMed Group's net